Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$27.04 USD
+0.44 (1.65%)
Updated May 10, 2024 04:00 PM ET
After-Market: $27.08 +0.04 (0.15%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
CORT 27.04 +0.44(1.65%)
Will CORT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CORT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CORT
United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales
Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates
CORT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for April 17th
Other News for CORT
10 Health Care Stocks With Whale Alerts In Today's Session
Corcept Therapeutics Breaks Above 200-Day Moving Average - Bullish for CORT
Corcept Therapeutics (CORT) Gets a Buy from Truist Financial
Corcept Therapeutics price target raised by $2 at H.C. Wainwright, here's why
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts